{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:03:54Z","timestamp":1793639034189,"version":"4.5.1"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Despite advances in surgical procedures and the optimization of immunosuppressive therapies in pediatric liver transplantation, acute rejection (AR) and serious adverse drug reaction (ADR) to tacrolimus still contribute to morbidity and mortality. Identifying risk factors of safety and efficacy parameters may help in optimizing individual immunosuppressive therapies. This study aimed to identify peritransplant predictors of AR and factors related to the risk of ADR to tacrolimus in a large Latin American cohort of pediatric liver transplant patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a retrospective cohort study in a pediatric liver transplant population (n = 72). Peritransplant variables were collected retrospectively including demographic, clinical, laboratory parameters, genomic (CYP3A5 donor and recipients polymorphism), and tacrolimus trough concentrations (C0) over a 2-year follow-up period. Variability in tacrolimus C0 was calculated using percent coefficient of variation and tortuosity. ADR- and AR-free survival rates were calculated using the Kaplan\u2013Meier method, and risk factors were identified by multivariate Cox regression models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Cox-proportional hazard models identified that high tortuosity in tacrolimus C0 was associated with an 80% increased risk of AR [hazard ratio (HR), 1.80; 95% confidence interval (CI), 1.01\u20133.22; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05], whereas steroid in maintenance doses decreased this risk (HR, 0.56; 95% CI, 0.31\u20130.99; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). Forty-six patients experienced at least one ADR including hypomagnesemia, nephrotoxicity, hypertension, malignancies, and tremor as a first event. Multivariate analysis showed that C0 values 10 days before the event (HR, 1.25; 95% CI, 1.21\u20131.39; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001) and CYP3A5 expresser recipients (HR, 2.05; 95% CI, 1.03\u20134.06; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05) were independent predictors of ADR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Tacrolimus C0 values, its variability, and CYP3A5 polymorphisms were identified as risk factors of AR and tacrolimus ADR. This knowledge may help to control and reduce their incidence in pediatric liver transplant patients. Prospective studies are important to validate these results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000517","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T13:24:58Z","timestamp":1523021098000},"page":"401-410","source":"Crossref","is-referenced-by-count":19,"title":["Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation"],"prefix":"10.1097","volume":"40","author":[{"given":"Natalia","family":"Riva","sequence":"first","affiliation":[{"name":"Unit of Clinical Pharmacokinetics, Hospital de Pediatr\u00eda J.P. Garrahan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Dip","sequence":"additional","affiliation":[{"name":"Liver Transplant Service, Hospital de Pediatr\u00eda J.P. Garrahan, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Halac","sequence":"additional","affiliation":[{"name":"Liver Transplant Service, Hospital de Pediatr\u00eda J.P. Garrahan, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"C\u00e1ceres Guido","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacokinetics, Hospital de Pediatr\u00eda J.P. Garrahan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean B.","family":"Woillard","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Centre Hospitalier Universitaire \u00e0 Limoges, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Licciardone","sequence":"additional","affiliation":[{"name":"Laboratory, Hospital de Pediatr\u00eda JP Garrahan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Chan","sequence":"additional","affiliation":[{"name":"Basic Science-Mathematics, Universidad Tecnol\u00f3gica Nacional;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferson","family":"Buend\u00eda","sequence":"additional","affiliation":[{"name":"Pharmacology Department, University of Buenos Aires;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Borgnia","sequence":"additional","affiliation":[{"name":"Microbiology Service, Hospital de Pediatr\u00eda JP Garrahan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bosaleh","sequence":"additional","affiliation":[{"name":"Pathology Service, Hospital de Pediatr\u00eda JP Garrahan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda T.","family":"de Davila","sequence":"additional","affiliation":[{"name":"Pathology Service, Hospital de Pediatr\u00eda JP Garrahan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Imventarza","sequence":"additional","affiliation":[{"name":"Liver Transplant Service, Hospital de Pediatr\u00eda J.P. Garrahan, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacokinetics, Hospital de Pediatr\u00eda J.P. Garrahan;"},{"name":"National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transpl Rev (Orlando)."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/petr.12627","article-title":"Outcomes of two-drug maintenance immunosuppression for pediatric renal transplantation: 10-yr follow-up in a single center","volume":"20","author":"Michael","year":"2016","journal-title":"Pediatr Transpl."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/archdischild-2013-305888","article-title":"Choosing the right dose of tacrolimus","volume":"100","author":"Lancia","year":"2015","journal-title":"Arch Dis Child."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1399-3046.2010.01437.x","article-title":"Safety and efficacy of tacrolimus in pediatric liver recipients","volume":"15","author":"Kelly","year":"2011","journal-title":"Pediatr Transpl."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1034\/j.1399-0012.1999.130301.x","article-title":"Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles","volume":"13","author":"Henry","year":"1999","journal-title":"Clin Transpl."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40272-015-0154-0","article-title":"Enhanced paediatric pharmacovigilance at the European Medicines Agency: a novel query applied to adverse drug reaction reports","volume":"18","author":"Blake","year":"2016","journal-title":"Paediatr Drugs."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jpeds.2011.10.038","article-title":"Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience","volume":"160","author":"Ng","year":"2012","journal-title":"J Pediatr."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/17512433.2016.1193434","article-title":"Therapeutic monitoring of immunosuppressive drugs in pediatric patients: special considerations","volume":"9","author":"Weber","year":"2016","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","article-title":"Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R12-20230814","first-page":"441","article-title":"Pharmacovigilance of calcineurin inhibitor in pediatric kidney and liver transplantation","volume":"37","author":"Riva","year":"2013","journal-title":"Farm Hosp."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"e12982","DOI":"10.1111\/petr.12982","article-title":"Pharmacoepidemiology of tacrolimus in pediatric liver transplantation","volume":"21","author":"Riva","year":"2017","journal-title":"Pediatr Transpl."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/00007890-199805150-00005","article-title":"An analysis of hepatic retransplantation in children","volume":"65","author":"Newell","year":"1998","journal-title":"Transplantation"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1600-6143.2007.02068.x","article-title":"Risk factors for rejection and infection in pediatric liver transplantation","volume":"8","author":"Shepherd","year":"2008","journal-title":"Am J Transpl."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1399-3046.2007.00794.x","article-title":"An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence","volume":"12","author":"Venkat","year":"2008","journal-title":"Pediatr Transpl."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1034\/j.1399-3046.2001.00020.x","article-title":"First experience with basiliximab in pediatric liver graft recipients","volume":"5","author":"Ganschow","year":"2001","journal-title":"Pediatr Transpl."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/S0140-6736(03)15104-5","article-title":"Steroid-free liver transplantation in children","volume":"362","author":"Reding","year":"2003","journal-title":"Lancet."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.trim.2006.09.033","article-title":"Clinical tolerance following liver transplantation: long term results and future prospects","volume":"17","author":"Mazariegos","year":"2007","journal-title":"Transpl Immunol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/lt.21397","article-title":"Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children","volume":"14","author":"Gras","year":"2008","journal-title":"Liver Transpl."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/S0041-1345(02)03144-5","article-title":"Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids","volume":"34","author":"Asensio","year":"2002","journal-title":"Transpl Proc."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2125.2012.04305.x","article-title":"Paediatric use of mycophenolate mofetil","volume":"75","author":"Downing","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(03)13175-3","article-title":"Tolerogenic immunosuppression for organ transplantation","volume":"361","author":"Starzl","year":"2003","journal-title":"Lancet."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transpl."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/lt.20065","article-title":"A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation","volume":"10","author":"Staatz","year":"2004","journal-title":"Liver Transpl."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"Naranjo ADR probability scale","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/FTD.0000000000000032","article-title":"Effects of combinational cyp3a5 6986a>g polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis","volume":"36","author":"Buendia","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"e87515","DOI":"10.1371\/journal.pone.0087515","article-title":"Quantification of tortuosity and fractal dimension of the lung vessels in pulmonary hypertension patients","volume":"9","author":"Helmberger","year":"2014","journal-title":"PLoS One."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1542\/peds.2008-1363","article-title":"Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a North American multicenter registry","volume":"122","author":"Ng","year":"2008","journal-title":"Pediatrics."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/adc.75.6.502","article-title":"Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy","volume":"75","author":"Murphy","year":"1996","journal-title":"Arch Dis Child."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1034\/j.1399-3046.2000.00127.x","article-title":"Intensive care management after pediatric liver transplantation: a single-center experience","volume":"4","author":"Ganschow","year":"2000","journal-title":"Pediatr Transpl."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/TP.0000000000001320","article-title":"Corticosteroid use and growth after pediatric solid organ transplantation: a systematic review and meta-analysis","volume":"101","author":"Tsampalieros","year":"2017","journal-title":"Transplantation."},{"key":"R41-20230814","first-page":"3","article-title":"Corticosteroid elimination in pediatric solid organ transplantation","volume":"2","author":"Fine","year":"1998","journal-title":"Pediatr Transpl."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation","volume":"51","author":"Bergmann","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00007890-199508270-00005","article-title":"Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients","volume":"60","author":"Keller","year":"1995","journal-title":"Transplantation."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1600-6143.2006.01406.x","article-title":"Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression","volume":"6","author":"Spada","year":"2006","journal-title":"Am J Transpl."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1399-3046.2008.00923.x","article-title":"Evaluating non-adherence to immunosuppressant medications in pediatric liver transplant recipients","volume":"12","author":"Stuber","year":"2008","journal-title":"Pediatr Transpl."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1399-3046.2010.01409.x","article-title":"Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children","volume":"14","author":"Pollock-Barziv","year":"2010","journal-title":"Pediatr Transpl."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1399-0012.2008.00834.x","article-title":"Do graft type or donor source affect acute rejection rates after liver transplant: a multivariate analysis","volume":"22","author":"Nguyen","year":"2008","journal-title":"Clin Transpl."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/TP.0000000000001394","article-title":"Influence of donor and recipient CYP3A4, CYP3A5, and ABCB1 genotypes on clinical outcomes and nephrotoxicity in liver transplant recipients","volume":"100","author":"Debette-Gratien","year":"2016","journal-title":"Transplantation."},{"key":"R49-20230814","first-page":"542","article-title":"Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients","volume":"41","author":"Venkataramanan","year":"2001","journal-title":"Transplantation."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","article-title":"Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation","volume":"62","author":"Kershner","year":"1996","journal-title":"Transplantation."},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1397-3142.2000.00000.x","article-title":"Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients","volume":"5","author":"MacFarlane","year":"2001","journal-title":"Pediatr Transpl."},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":"CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"R53-20230814","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/ndt\/gfr253","article-title":"CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation","volume":"26","author":"Glowacki","year":"2011","journal-title":"Nephrol Dial Transpl."},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FPC.0b013e3282f9ac01","article-title":"Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients","volume":"18","author":"Fukudo","year":"2008","journal-title":"Pharmacogenet Genomics."},{"key":"R55-20230814","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FTD.0b013e3181e06818","article-title":"Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients","volume":"32","author":"Kuypers","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther."},{"key":"R57-20230814","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00007.x","article-title":"Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients","volume":"48","author":"Bottiger","year":"1999","journal-title":"Br J Clin Pharmacol."},{"key":"R58-20230814","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med."},{"key":"R59-20230814","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1124\/dmd.105.005611","article-title":"Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age","volume":"33","author":"Fakhoury","year":"2005","journal-title":"Drug Metab Dispos."},{"key":"R60-20230814","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","article-title":"Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation","volume":"69","author":"Guy-Viterbo","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R61-20230814","first-page":"142","article-title":"Current status and regulation of bioanalytical laboratories engaged in quantifying immunosuppressants for transplant patients in Argentina [in Spanish]","volume":"39","author":"Schaiquevich","year":"2016","journal-title":"Rev Panam Salud Publica."},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/clinchem\/42.9.1426","article-title":"Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients","volume":"42","author":"Gonschior","year":"1996","journal-title":"Clin Chem."},{"key":"R63-20230814","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jsps.2015.01.010","article-title":"Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions","volume":"24","author":"Khan","year":"2016","journal-title":"Saudi Pharm J."},{"key":"R64-20230814","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions: a systematic review","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf."},{"key":"R65-20230814","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/pds.1138","article-title":"Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel","volume":"14","author":"Macedo","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"R66-20230814","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40264-013-0083-1","article-title":"Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference","volume":"36","author":"Theophile","year":"2013","journal-title":"Drug Saf."},{"key":"R67-20230814","doi-asserted-by":"crossref","first-page":"e0171470","DOI":"10.1371\/journal.pone.0171470","article-title":"Imputation of adverse drug reactions: causality assessment in hospitals","volume":"12","author":"Varallo","year":"2017","journal-title":"PLoS One."},{"key":"R68-20230814","doi-asserted-by":"crossref","first-page":"e4439","DOI":"10.1371\/journal.pone.0004439","article-title":"Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes","volume":"4","author":"Davies","year":"2009","journal-title":"PLoS One."},{"key":"R69-20230814","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00228-010-0987-y","article-title":"Adverse drug events in an intensive care unit of a university hospital","volume":"67","author":"Reis","year":"2011","journal-title":"Eur J Clin Pharmacol."},{"key":"R70-20230814","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/BF03261961","article-title":"Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs","volume":"35","author":"Kane-Gill","year":"2012","journal-title":"Drug Saf."},{"key":"R71-20230814","first-page":"17","article-title":"An investigation of disagreement in causality assessment of adverse drug reactions","volume":"25","author":"Davies","year":"2011","journal-title":"Pharmaceut Med."},{"key":"R72-20230814","first-page":"150","article-title":"Therapeutic monitoring of pediatric transplant patients with conversion to generic tacrolimus","volume":"41","author":"Riva","year":"2017","journal-title":"Farm Hosp."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:17:14Z","timestamp":1692051434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000517","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}